Investor RelationsPress RoomCOVID-19
  1. Home
  2. Laboratory Diagnostics
  3. Assays by Diseases and Conditions
  4. Reproductive Endocrinology
  5. New sFlt-1 and PlGF assays to aid in the prognosis of preeclampsia
repro-endo maral woman key visual

New sFlt-1 and PlGF assays to aid in the prognosis of preeclampsia

High performing reproductive endocrinology assays

Preeclampsia (PE) is a type of hypertensive disorder of pregnancy characterized by high blood pressure, and proteinuria. PE occurs in 2–8% of pregnancies and potentially contributes to significant fetal, neonatal, and maternal morbidity and mortality.1 The addition of the Siemens Healthineers sFlt-1 and PlGF assays, prognostic markers for preeclampsia, to improve the management of this condition. 

Epidemiology

Preeclampsia prevalence woman

Prevalence:

  • Most common medical pathology of pregnancy
  • 2-8% of pregnancies, depending on region
  • U.S. prevalence = 3.4%
  • Worldwide prevalence = 4.6%
  • 0.3% prevalence <34 weeks
  • 2.7% prevalence >34 weeks
  • ~25% PE → PE with severe features
Preeclampsia demographics women

Demographics:

  • Highest incidence in low-income countries
  • Risk of developing PE is 7x greater in developing countries
  • Most common in first-time pregnancies
  • ~80% develop between 37-40 weeks and are uneventful
  • 40% accounted for by women with overweight or obesity before conception  

 Atellica® IM sFlt-1 and PlGF Performance Characteristics

Reproductive Endocrinology - Measuring a lifetime of Changes

Reproductive Care for a Lifetime

Reproductive endocrinology covers a wide range of endocrine disorders related to the reproductive system in both males and females, including puberty and menstrual cycles, infertility, pregnancy, and menopause. As a longstanding leader in reproductive endocrinology, Siemens Healthineers offers a broad range of systems and assays to address the various clinical needs in reproductive health.

“We evaluated the analytical performance of Siemens Healthineers ADVIA Centaur PlGF and sFlt-1 assays (5-days precision study, 2 runs per day, 5 replicates each run) and we were pleased with the results that demonstrated robust precision. Also, there was a close alignment between the methods when compared to commercially available assays. The PlGF and sFlt-1 biomarkers address the unmet need for early detection of preeclampsia and improve patient outcomes.”

Dr. P. Apostolakopoulos
REA Maternity Hospital
Athens, Greece

1

American College of Obstetrics and Gynecology (ACOG) Practice Bulletin No. 222: Obstet Gynecol 2020;135:e237-e260

August et al. UpToDate 2019 Preeclampsia: Clinical features and diagnosis Lisonkova S, et al. Obstet Gynecol 2014;124:771-81. World Health Report: Women's and Children's Health. In: WHO, ed. Geneva, Switzerland. 2005

The statements by Siemens Healthineers’ customers described herein are based on results that were achieved in the customer's unique setting. Because there is no “typical” hospital or laboratory and many variables exist (e.g., hospital size, samples mix, case mix, level of IT and/or automation adoption) there can be no guarantee that other customers will achieve the same results.

Not available for sale in the US. The products (mentioned herein) are not commercially available in all countries. Their future availability cannot be guaranteed.